2016 MemoriesSpecial Report...Early 2016 Theralase Technologies, Inc. Our next biotech "home run??" HIGHLIGHTS: * Having brought our subscribers MONSTER quadruple-digit gains in the recent past with Sarepta Therapeutics (NASD-SRPT) and Anavex Life Sciences (NASDAVXL), our sights are now set on Theralase Technologies. * Unlike most early-stage biotech companies, Theralase has a CURRENT cash-generating business in therapeutic lasers. This, in part, will help fund its research work into the potentially breakthrough technology it is pursuing in cancer treatment and eradication. * Now cleared to sell its next generation therapeutic product in both the U.S. and Canada, cash flow should increase substantially in 2016. (Above, you see the new TLC-2000, which management believes can generate some $50 million in revenue annually within five years.) * Also in 2016 we should get our next results on Theralase's cancer research. This division holds the prospect of this company being our next "home run." If current trials bring positive results, shares could SOAR from their present level!